{"id":22704,"date":"2026-02-24T06:35:13","date_gmt":"2026-02-24T06:35:13","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/22704\/"},"modified":"2026-02-24T06:35:13","modified_gmt":"2026-02-24T06:35:13","slug":"whats-next-for-novo-nordisk-stock","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/22704\/","title":{"rendered":"What’s Next For Novo Nordisk Stock?"},"content":{"rendered":"

Novo Nordisk\u2019s stock fell 16% on February 23rd after clinical trial results showed that its experimental weight-loss pill, CagriSema, underperformed relative to Eli Lilly\u2019s<\/a> competing drug, Mounjaro. The trial data revealed that CagriSema achieved lower weight reduction outcomes than Lilly\u2019s GLP-1 therapy, a meaningful blow given that the obesity drug race is increasingly winner-takes-most. This single-day drop now brings NVO\u2019s twelve-month return to -56%. The obvious question: Is this a buying opportunity? We don\u2019t think so.<\/p>\n

But, before we delve into the details, if you seek an upside with less volatility than holding an individual stock like NVO, consider the High Quality Portfolio<\/a>. It has comfortably outperformed its benchmark \u2013 a combination of the S&P 500, Russell, and S&P MidCap indexes \u2013 and has achieved returns exceeding 105% since its inception. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.<\/a> On a separate note, see \u2013 Ethereum Solved Its Scaling Problem. That\u2019s the Problem.<\/a><\/p>\n

\"weighing<\/p>\n

Photo by Memed_Nurrohmad<\/a> on Pixabay<\/a><\/p>\n

Let\u2019s start with the fundamentals<\/p>\n

Novo Nordisk\u2019s revenue grew 11% over the last twelve months to $46.9 billion \u2013 respectable in isolation, but a sharp deceleration from the three-year average growth rate of 24%. Margins tell a similar story. Operating profit margin sits at 41.3%, down from a three-year average of 43.2%, and operating cash flow margin has slipped to 39% from 42%. So the business is still highly profitable, but the trajectory is moving in the wrong direction on both growth and margins simultaneously. That matters.<\/p>\n

The balance sheet, to its credit, remains solid. Debt-to-equity stands at 11% \u2013 elevated relative to prior levels largely because the falling stock price has compressed the equity base, not because the company has been reckless with borrowing. Cash as a percentage of assets is around 5%, which is lean but manageable for a company generating cash at this scale. No red flags here.<\/p>\n

Is the valuation attractive enough?<\/p>\n

At roughly $40 per share, NVO trades at 11x trailing earnings of $3.49 \u2013 well below its three-year average of 26x, and cheaper than peers like LLY, ABBV, and JNJ. On the surface, that looks compelling. But valuation alone is rarely sufficient reason to buy a stock, and this is a case where the multiple compression is telling you something important: the market is reassessing the long-term earnings power of the business, not just being irrationally pessimistic.<\/p>\n

The premium NVO commanded was built on the expectation that it would be a dominant, perhaps co-dominant, player in the GLP-1 weight loss market. That thesis is now under pressure. Wall Street analysts have already begun lowering their ratings, citing a long-term clinical edge in favor of Eli Lilly. The average analyst price target of $57 will likely face downward revisions \u2013 meaning the apparent upside in that number is probably overstated right now.<\/p>\n

So, should you buy the dip?<\/p>\n

We don\u2019t think so. At least not yet. Yes, the stock is cheap relative to its own history. And yes, a -56% drawdown over twelve months is dramatic. But the core risk here isn\u2019t valuation; it\u2019s narrative. When a company loses its clinical edge in the market that drove its premium, the re-rating process rarely ends in a single day. Negative sentiment tends to persist until there\u2019s a concrete catalyst to reverse it \u2013 new trial data, a partnership, or a competitive surprise \u2013 none of which are visible on the horizon right now.<\/p>\n

Could we be wrong? Absolutely. Stocks that have fallen this far can rebound sharply on even marginally better news, and NVO\u2019s underlying business, with $46.9 billion in revenue and 41% operating margins, is far from broken. Investors with a long time horizon and high risk tolerance might find the current price defensible as a small position.<\/p>\n

But from a pure risk-reward standpoint, if the thesis is exposure to the weight loss drug space, LLY remains the stronger play. Its clinical lead is now more established, and while its valuation is far from cheap, you\u2019re paying for a clearer path to dominance. In a winner-takes-most market, that clarity is worth a premium.<\/p>\n

The Best Investors Think In Portfolios<\/p>\n

Individual stocks like NVO are unpredictable. A smart portfolio helps you invest, limits downside shocks, and provides upside exposure. The Trefis High Quality (HQ) Portfolio<\/a>, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 \u2013 the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? HQ Portfolio has posted more than 105% in cumulative return since inception, with less risk versus the benchmark index, as evident in HQ Portfolio performance metrics<\/a>.<\/p>\n

Invest with\u00a0Trefis\u00a0Market-Beating Portfolios<\/a>
See all\u00a0Trefis\u00a0Price Estimates<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Novo Nordisk\u2019s stock fell 16% on February 23rd after clinical trial results showed that its experimental weight-loss pill,…\n","protected":false},"author":2,"featured_media":22705,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[276,3860,15275,272,3859,3582,15274],"class_list":["post-22704","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-eli-lilly","tag-lly","tag-mrk","tag-novo-nordisk","tag-nvo","tag-nvo-stock","tag-pfe"],"share_on_mastodon":{"url":"","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/22704","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=22704"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/22704\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/22705"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=22704"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=22704"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=22704"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}